ArticleCancers2019
Validation of Immunohistochemistry for the Detection of
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Diagnostic role of BRAF VE1 immunohistochemistry to distinguish benign ciliated epithelium from malignant epithelium in small pulmonary biopsies.Virchows Archiv : an international journal of pathology · 2026Article
- Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521.JCO global oncology · 2024Article
- BRAFNPJ precision oncology · 2024Review
- Article
- Survival outcomes and prognostic factors of lung cancer patients with theFrontiers in oncology · 2023Article
- Assessment of BRAF V600E (VE1) immunochemistry for the detection of BRAF V600E mutation in non-small cell lung carcinoma cytology specimens.Cancer cytopathology · 2023Article
- Usefulness of BRAF VE1 immunohistochemistry in non-small cell lung cancers: a multi-institutional study by 15 pathologists in Korea.Journal of pathology and translational medicine · 2022Article
- Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing.Journal of personalized medicine · 2022Review
- Selection Strategies and Practical Application of BRAF V600E-Mutated Non-Small Cell Lung Carcinoma.Cancer research and treatment · 2022Article
- The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: a multi-institutional retrospective study in Taiwan.American journal of cancer research · 2022Article
- [Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant Advanced Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Review
- Clinicopathological Features and Survival Outcomes of Primary Pulmonary Invasive Mucinous Adenocarcinoma.Cancers · 2021Article
- VE1 immunohistochemistry is an adjunct tool for detection of BRAFJournal of clinical laboratory analysis · 2021Article
- A highly sensitive and specific real-time quantitative PCR for BRAF V600E/K mutation screening.Scientific reports · 2020Article
- Immunocytochemistry of cytology specimens for predictive biomarkers in lung cancer.Translational lung cancer research · 2020Review
- Immunohistochemical Study Using Monoclonal VE1 Antibody Can Substitute the Molecular Tests for Apprehension of BRAF V600E Mutation in Patients with Non-small-Cell Lung Carcinoma.Analytical cellular pathology (Amsterdam) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.